Viral-specific cytotoxic T lymphocytes lyse human immunodeficiency virus-infected primary T lymphocytes by the granule exocytosis pathway

Blood

Volumn 94, Issue 9, 1999, Pages 3084-3093

  Shankar, Premlata ^a   Xu, Zhan ^a   Lieberman, Judy ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTER FOR BLOOD RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL GRANULE; CELL LINE; CYTOTOXIC T LYMPHOCYTE; EXOCYTOSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; LYMPHOBLASTOID CELL; LYMPHOCYTOTOXICITY; PRIORITY JOURNAL;

EID: 0033229708     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.9.3084     Document Type: Article

References (73)

1. McMichael AJ, Walker BD: Cytotoxic T lymphocyte epitopes: Implications for HIV vaccines. AIDS 8:155, 1994
2. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68:4650, 1994
3. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68:6103, 1994
4. Safrit JT, Koup RA: The immunology of primary HIV infection: Which immune responses control HIV replication? Curr Opin Immunol 7:456, 1995
5. Riviere Y, McChesney MB, Porrot F, Tanneau-Salvadori F, Sansonetti P, Lopez O, Pialoux G, Feuillie V, Mollereau M, Chamaret S, Takaia F, Montagnier L: Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 11:903, 1995
6. + cells in human immunodeficiency virus type I pathogenesis: Cytolytic and noncytolytic inhibition of viral replication. Adv Immunol 66:273, 1997
7. Finkel TH, Banda NK: Indirect mechanisms of HIV pathogenesis: How does HIV kill T cells? Curr Opin Immunol 6:605, 1994
8. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, Kupfer A: Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nature Med 1:129, 1995
9. Burrows SR, Fernan A, Argaet V, Suhrbier A: Bystander apoptosis induced by CD8+ cytotoxic T cell (CTL) clones: Implications for CTL lytic mechanisms. Int Immunol 5:1049, 1993
10. Ando K, Hiroishi K, Kaneko T, Moriyama T, Muto Y, Kayagaki N, Yagita H, Okumura K, Imawari M: Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 158:5283, 1997
11. + T cells is a marker of poor prognosis in HIV infection: Results of 6 years of follow-up. Cytometry 26:1, 1996
12. + T cells in HIV-1-infected patients. AIDS 10:827, 1996
13. Roederer M, Herzenberg LA, Herzenberg LA: Changes in antigen densities on leukocyte subsets correlate with progression of HIV disease. Int Immunol 8:1, 1996
14. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 16:83, 1997
15. + lymphocyte percent: A useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 14:158, 1997
16. 51Cr-release assay? J Exp Med 164:1075, 1986
17. Cannon MJ, Openshaw PJ, Askonas BA: Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 168:1163, 1988
18. Barnaba V, Franco A, Alberti A, Balsano C, Benvenuto R, Balsano F: Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection. J Immunol 143:2650, 1989
19. Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R, Walker BD: Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 149:3339, 1992
20. Ando K, Moriyama T, Guidotti LG, Wirth S, Schreiber RD, Schlicht HJ, Huang SN, Chisari FV: Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 178:1541, 1993
21. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, Fusamoto H, Kamada T: Immunohistochemical detection of fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 19:1354, 1994
22. Mita E, Hayashi N, Iio S, Takehara T, Hijioka T, Kasahara A, Fusamoto H, Kamada T: Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 204:468, 1994
23. Ohishi M, Sakisaka S, Koji T, Nakane PK, Tanikawa K: The localization of HCV and the expression of fas antigen in the liver of HCV-related chronic liver disease. Acta Histochem Cytochem 28:341, 1995
24. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L: Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182:1223, 1995
25. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528, 1994
26. Kojima H, Shinohara N, Hanaoka S, Someya-Shirota Y, Takagaki Y, Ohno H, Saito T, Katayama T, Yagita H, Okumura K, Shinkai Y, Alt FW, Matsuzawa A, Yonehara S, Takayama H: Two distinct pathways of specific killing revealed by perform mutant cytotoxic T lymphocytes. Immunity 1:357, 1994
27. Kagi D, Ledermann B, Burki K, Zinkernagel RM, Hengartner H: Lymphocyte-mediated cytotoxicity in vitro and in vivo: Mechanisms and significance. Immunol Rev 146:95, 1995
28. Podack ER: Functional significance of two cytolytic pathways of cytotoxic T lymphocytes. J Leukoc Biol 57:548, 1995
29. Hudig D, Ewoldt GR, Woodard SL: Proteases and lymphocyte cytotoxic killing mechanisms. Curr Opin Immunol 5:90, 1993
30. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ: Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76:977, 1994
31. Henkart PA: Lymphocyte-mediated cytotoxicity: Two pathways and multiple effector molecules. Immunity 1:343, 1994
32. +)-independent T cell-mediated cytotoxicity. J Exp Med 177:195, 1993
33. Hanabuchi S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, Nishimura Y, Kobayashi Y, Yonehara S, Yagita H, Okumura K: Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci USA 91:4930, 1994
34. Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly RP, Finkel TH: Crosslinking CD4 by human immunodeficiency virus gp 120 primes T cells for activation-induced apoptosis. J Exp Med 176:1099, 1992
35. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, Debatin KM, Krammer PH: Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375:497, 1995
36. Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA, Herzenberg LA: Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med 181:2029, 1995
37. Oyaizu N, McCloskey TW, Than S, Hu R, Kalyanaraman VS, Pahwa S: Cross-linking of CD4 molecules upregulates fas antigen expression in lymphocytes by inducing interferon-γ and tumor necrosis factor-α secretion. Blood 84:2622, 1994
38. Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, Aldovini A, Young R, Moss B, Schooley RT: Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci USA 86:9514, 1989
39. Lieberman J, Fabry JA, Kuo MC, Earl P, Moss B, Skolnik PR: Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase. J Immunol 148:2738, 1992
40. Lieberman J, Fabry JA, Shankar P, Beckett L, Skolnik PR: Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects. AIDS Res Hum Retroviruses 11:257, 1995
41. Chen BK, Gandhi RT, Baltimore D: CD4 Down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J Virol 70:6044, 1996
42. Shankar P, Sprang H, Lieberman J: Effective lysis of HIV-infected primary CD4 T cells by a cytotoxic T lymphocyte clone directed against a novel A2-restricted reverse transcriptase epitope. J Acquir Immune Syndr Hum Retrovirol 19:111, 1998
43. Shankar P, Fabry JA, Fong DM, Lieberman J: Three regions of HIV-1 gp160 contain clusters of immunodominant CTL epitopes. Immunol Lett 52:23, 1996
44. Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, Corey LC, Bolognesi DP, Weinhold KJ: Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 94:1396, 1997
45. Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, McMichael AJ: HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 336: 484, 1988
46. Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S, Nagai K: Concanamycin A, a powerful tool for characterization and estimation of contribution of perform- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 156:3678, 1996
47. Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM: Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94, 1996
48. Trimble LA, Lieberman J: Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex. Blood 91:585, 1998
49. Montel AH, Bochan MR, Goebel WS, Brahmi Z: Fas-mediated cytotoxicity remains intact in perform and granzyme B antisense transfectants of a human NK-like cell line. Cell Immunol 165:312, 1995
50. Borthwick NJ, Bofill M, Gombert WM, Akbar AN, Medina E, Sagawa K, Lipman MC, Johnson MA, Janossy G: Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28-T cells. Acta Chem Scand 8:431, 1994
51. + T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity. Int Immunol 10:311, 1998
52. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: Metalloproteinase-mediated release of human fas ligand. J Exp Med 182:1777, 1995
53. Kagi D, Hengartner H: Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Curr Opin Immunol 8:472, 1996
54. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31, 1994
55. Kagi D, Seiler P, Pavlovic J, Ledermann B, Burki K, Zinkemagel RM, Hengartner H: The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol 25:3256, 1995
56. + CTL clones resist fas ligand-induced apoptosis and use fas/fas ligand-independent mechanisms for tumor killing. J Immunol 161:1220, 1998
57. Stenger S, Mazzaccaro RJ, Uyemura K, Cho S, Barnes PF, Rosat JP, Sette A, Brenner MB, Porcelli SA, Bloom BR, Modlin RL: Differential effects of cytolytic T cell subsets on intracellular infection. Science 276:1684, 1997
58. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314, 1992
59. Takahashi T, Tanaka M, Brannan Cl, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969, 1994
60. Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N, Nagata S: Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 11:294, 1995
61. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935, 1995
62. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347, 1995
63. + cytotoxic T lymphocyte clones. Eur J Immunol 25:3381, 1995
64. + T cells by a self-derived peptide. Nature 378:295, 1995
65. Tsujimura K, Takahashi T, Iwase S, Matsudaira Y, Kaneko Y, Yagita H, Obata Y: Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: Differences in cytotoxic mechanisms and accessory molecule requirements. J Immunol 160:5253, 1998
66. Zinkernagel RM: Are HIV-specific CTL responses salutary or pathogenic? Curr Opin Immunol 7:462, 1995
67. Zinkernagel RM, Hengartner H: T-cell-mediated immunopathology versus direct cytolysis by virus: Implications for HIV and AIDS. Immunol Today 15:262, 1994
68. Garcia S, Fevrier M, Dadaglio G, Lecoeur H, Riviere Y, Gougeon ML: Potential deleterious effect of anti-viral cytotoxic lymphocyte through the CD95 (FAS/APO-1)-mediated pathway during chronic HIV infection. Immunol Lett 57:53, 1997
69. Johnson RP: Upregulation of Fas ligand by simian immunodeficiency virus - A nef-arious mechanism of immune evasion? J Exp Med 186:1, 1997
70. Tsomides TJ, Aldovini A, Johnson RP, Walker BD, Young RA, Eisen HN: Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med 180:1283, 1994
71. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D: HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391:397, 1998
72. Xu XN, Screaton GR, Gotch FM, Dong T, Tan R, Almond N, Walker B, Stebbings R, Kent K, Nagata S, Stott JE, McMichael AJ: Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells. J Exp Med 186:7, 1997
73. + T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med 185:55, 1997